FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
20 févr. 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
14 févr. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the first subject has been dosed at Erasmus Medical Center (“Erasmus...
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
05 févr. 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
25 janv. 2024 07h00 HE
|
FibroGen, Inc.
Pamrevlumab has now completed Stage 2 of the trial and topline data from this registration study in ~175 pamrevlumab treated patients is anticipated in 2Q 2024Pamrevlumab is the first experimental arm...
Metastatic Non-Small Cell Lung Cancer Market to Surge with a Potential USD 45 Billion Valuation by 2032, Reveals New Comprehensive Analysis
24 janv. 2024 10h28 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Non-Small Cell Lung Cancer - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's...
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
24 janv. 2024 09h10 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has received authorization from the Erasmus Medical Center...
Oncology Nutrition Market Experiences Growth with Rise in Personalized and Immuno-nutrition Trends
22 janv. 2024 21h28 HE
|
Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The recent comprehensive analysis within...
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
22 janv. 2024 08h55 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the first subject has been enrolled at Erasmus Medical Center...
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
10 janv. 2024 08h45 HE
|
AIM ImmunoTech Inc.
First enrollment and first subject dosing expected soon at Erasmus Medical Center in Rotterdam, Netherlands Management discusses the announcement and what this means here: video OCALA, Fla.,...
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
09 janv. 2024 10h25 HE
|
FN Media Group LLC
PALM BEACH, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to the report titled "Aging in the United States," published by the Population Reference Bureau, "the...